FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, GlycoNex's Trailing 12-Month Free Cash Flow is NT$-172.86 Mil, and Market Cap is NT$2,869.29 Mil. Therefore, GlycoNex's FCF Yield % for today is -6.02%.
The historical rank and industry rank for GlycoNex's FCF Yield % or its related term are showing as below:
ROCO:4168'
s FCF Yield % Range Over the Past 10 Years
Min: -21.12 Med: -7.68 Max: -3.41
Current: -6.02
During the past 13 years, the highest FCF Yield % of GlycoNex was -3.41%. The lowest was -21.12%. And the median was -7.68%.
ROCO:4168's FCF Yield % is ranked better than 58.91% of 1409
companies
in the Biotechnology industry
Industry Median: -9.25
vs ROCO:4168: -6.02
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
GlycoNex FCF Yield % Related Terms
GlycoNex FCF Yield % Historical Data
* Premium members only.
The historical data trend for GlycoNex's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4168 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, GlycoNex's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoNex FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoNex's FCF Yield % distribution charts can be found below:
* The bar in red indicates where GlycoNex's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoNex (ROCO:4168) has a FCF Yield % of -6.02 as of Jul. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on GlycoNex and its competitors. According to the industry distribution chart, GlycoNex ranks #579 out of 1409 companies in the Biotechnology industry, placing it in the top 41.1%.
Is GlycoNex's FCF Yield % too high?
GlycoNex's current FCF Yield % is -6.02. Based on the distribution chart, GlycoNex ranks #579 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GlycoNex has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GlycoNex ranks #579 out of 1409 companies for FCF Yield %. This puts GlycoNex in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on GlycoNex and its competitors. GlycoNex's current FCF Yield % is -6.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$74.67, compared to a current price of NT$25.50 — trading 65.8% below its estimated fair value. The current FCF Yield % is -6.02. GlycoNex's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current FCF Yield % is -6.02 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlycoNex (ROCO:4168) Overvalued in 2026?
Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued.
The current stock price of NT$25.50 is trading 65.8% below its estimated GF Value™ of NT$74.67.
GuruFocus considers GlycoNex to be Significantly Undervalued.
Key valuation signals for ROCO:4168:
FCF Yield %: -6.02
GF Value™: NT$74.67 vs. price of NT$25.50 (65.8% below fair value)
No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
56GF Score
Get the complete analysis for ROCO:4168
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4168 has been successfully added to your 
